Unlocking Hope for Cancer Patients Using PDT
4
BACKGROUND AND DEVELOPMENT TIMEFRAME: CANCER
PATHWAY TO CLINICAL TRIALS
Partnership with
Peter Mac
Potential in
metastatic
cancers
Photosoft
destroys
ovarian cancer
in vitro
Partnership
with Hudson
Institute
Reverse
merger
into IVX
Discovery/Pre-clinical
for IVX-P02/P03
COVID-19 Lockdowns
PoC 2: Complete
regression of TNBC
PoC 1:
INV043
effective
PoC 3: INV043
significantly improves
ICI therapy
INV043 effective
against anal
cancer SCC in vitro
HUDSON
INSTITUTE OF MEDICAL RESEARCH
GMP
manufacturing
with IDT Australia
Additional Indications*
Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia
against
multiple
cancers
Australian patent
granted covering
INV043
Phase 1 clinical trials
Pre-clinical for new API INV043 /
Portfolio of new compounds
2013 ...
2017
2021
2023
2024
2025
idt
australia
Additional Indications*
Phase 1b/2
clinical trials
*Indicative timelines
>2025
INVIONView entire presentation